ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,187.70
0.13%
Dow Jones
38,884.26
0.08%
US Dollar vs MXN
16.9349
0.17%
Brent Oil
82.685
-0.22%
Bitcoin
62,778.13
0.71%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. EyePoint Pharmaceuticals Inc (EYPT)

  7. EyePoint Pharmaceuticals Inc (EYPT) Noticias

EYPT

EyePoint Pharmaceuticals (EYPT)

EyePoint Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:EYPT
FechaHoraFuenteTítuloSímboloCompañía
06/05/202408:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EYPTEyePoint Pharmaceuticals Inc
06/05/202406:00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic RetinopathyNASDAQ:EYPTEyePoint Pharmaceuticals Inc
16/04/202406:00GlobeNewswire Inc.EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:EYPTEyePoint Pharmaceuticals Inc
02/04/202406:00GlobeNewswire Inc.EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina SpecialistsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
08/03/202412:53Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
07/03/202406:00GlobeNewswire Inc.EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate DevelopmentsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
04/03/202416:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
04/03/202416:37Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
04/03/202406:00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical OfficerNASDAQ:EYPTEyePoint Pharmaceuticals Inc
29/02/202406:00GlobeNewswire Inc.EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024NASDAQ:EYPTEyePoint Pharmaceuticals Inc
27/02/202406:00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Participation at Upcoming Investor ConferencesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
14/02/202420:08Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
03/02/202415:20GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular DegenerationNASDAQ:EYPTEyePoint Pharmaceuticals Inc
02/02/202415:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
31/01/202406:00GlobeNewswire Inc.EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:EYPTEyePoint Pharmaceuticals Inc
10/01/202406:00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular EdemaNASDAQ:EYPTEyePoint Pharmaceuticals Inc
03/01/202417:37Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
20/12/202306:00GlobeNewswire Inc.EyePoint Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:EYPTEyePoint Pharmaceuticals Inc
08/12/202316:28Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
08/12/202315:01GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional SharesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
07/12/202305:11Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
05/12/202319:18GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Pricing of Upsized Public OfferingNASDAQ:EYPTEyePoint Pharmaceuticals Inc
05/12/202305:25IH Market NewsMoody’s Reassesses China, GitLab Exceeds Estimates, Twilio Plans Major Layoffs, and MoreNASDAQ:EYPTEyePoint Pharmaceuticals Inc
04/12/202315:34Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
04/12/202315:06GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Proposed Public Offering of Common StockNASDAQ:EYPTEyePoint Pharmaceuticals Inc
04/12/202306:00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD Achieving All Primary and Secondary EndpointsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
03/11/202314:47Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
01/11/202306:00GlobeNewswire Inc.EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate DevelopmentsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
31/10/202306:00GlobeNewswire Inc.EyePoint Pharmaceuticals to Host Virtual Key Opinion Leader (KOL) Event on November 9, 2023NASDAQ:EYPTEyePoint Pharmaceuticals Inc
30/10/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:EYPTEyePoint Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:EYPT

Su Consulta Reciente

FX
EURUSD
Euro vs US Dollar
USOTC
RHHBY
Roche (QX)
NASDAQ
GOOGL
Alphabet
USOTC
BASFY
BASF (QX)
COIN
ETHUSD
Ethereum
COIN
SOLUSD
Solana
FX
USDMXN
US Dollar vs MXN
USOTC
ADDYY
Adidas (QX)
USOTC
BNPQY
BNP Paribas (QX)
USI
USTECH100
US Tech 100
PM
XAUUSD
Gold vs US Dollar
NYSE
VZ
Verizon Communications
NASDAQ
MSFT
Microsoft
CCOM
SILVER
SILVER
NYSE
AXP
American Express
NASDAQ
QQQ
Invesco QQQ Trust Series 1
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados